The Ethics of Elective Growth Hormone Therapy in Children with Idiopathic Short Stature.

Q3 Medicine

Journal of Clinical Ethics Pub Date : 2021-01-01

Kevin Leslie Kecskemeti, Samuel Reis-Dennis

引用次数: 0

Abstract

In this article, we analyze the ethics of elective growth hormone (GH) therapy in children with idiopathic short stature (ISS). We discuss recent clinical research regarding the efficacy, side-effects, and risks of GH therapy, and argue that GH therapy is ethically unjustifiable for most children with ISS.

本刊更多论文

特发性矮小儿童选择性生长激素治疗的伦理学。

在本文中，我们分析选择性生长激素(GH)治疗儿童特发性身材矮小(ISS)的伦理。我们讨论了最近关于生长激素治疗的疗效、副作用和风险的临床研究，并认为生长激素治疗对大多数ISS儿童在伦理上是不合理的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Ethics Medicine-Medicine (all)

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Journal of Clinical Ethics is written for and by physicians, nurses, attorneys, clergy, ethicists, and others whose decisions directly affect patients. More than 70 percent of the articles are authored or co-authored by physicians. JCE is a double-blinded, peer-reviewed journal indexed in PubMed, Current Contents/Social & Behavioral Sciences, the Cumulative Index to Nursing & Allied Health Literature, and other indexes.